Shares declined 4.3% after Insulet’s earnings call as investors reacted negatively to a cautious outlook shaped by seasonal headwinds in the U.S. diabetes market and modest deceleration in early-year revenue trends, despite raised full-year guidance.

• Reported 30% revenue growth in Q1 2026, including 28% growth in the U.S. and 45% internationally.
• Adjusted operating margin expanded by 110 basis points year-over-year, driving roughly 40% adjusted EPS growth.
• Management cited unusual seasonality effects from annual insurance deductible resets, causing a slower start in U.S. market demand.
• Though full-year revenue growth guidance was slightly raised to 21–23%, early quarter softness and cautious tone on U.S. trends weighed on sentiment.
• Continued progress internationally with strong new customer starts and expanded reimbursement coverage, particularly in Canada and Europe.